A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2001
10/25/2001	US20010034361 Amide derivatives for antiangiogenic and/or antitumorigenic use
10/25/2001	US20010034351 A quinazoline compound
10/25/2001	US20010034347 A pyrido(1,2-a)pyrazine compound
10/25/2001	US20010034340 Hormone replacement therapy
10/25/2001	US20010034337 Antiproliferative agents
10/25/2001	US20010034334 Genetic engineered polypeptide
10/25/2001	US20010034331 Isolated polypeptide
10/25/2001	US20010034329 Nucleic acids
10/25/2001	US20010034327 Suppression of inhibitors
10/25/2001	US20010034051 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
10/25/2001	US20010034042 Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
10/25/2001	US20010034021 Antibodies that specifically react with seroreactive regions on HPV 16 proteins E1 and E2
10/25/2001	US20010033861 Liposomes containing an entrapped compound in supersaturated solution
10/25/2001	US20010033845 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
10/25/2001	DE10020899A1 New 9-oxa-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
10/25/2001	DE10020517A1 New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
10/25/2001	DE10020125A1 Agent for stimulating bone regrowth, useful as insert after surgery for bone cancer, comprises single sequence expressing a fusion of growth factor and protease inhibitor
10/25/2001	DE10019062A1 Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia
10/25/2001	DE10018681A1 Composition for autologous tumor treatment, comprises extracellular material produced by culturing immune competent cells with tumor cells that lack membrane surface substances
10/25/2001	CA2747325A1 Albumin fusion proteins
10/25/2001	CA2409190A1 Poliovirus replicons encoding therapeutic agents and uses thereof
10/25/2001	CA2407531A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001	CA2407065A1 A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
10/25/2001	CA2406590A1 Agent for postoperative use after the removal of bone tumours
10/25/2001	CA2406472A1 Javelinization of protein antigens to heat shock proteins
10/25/2001	CA2406442A1 Hydrazide and alkoxyamide angiogenesis inhibitors
10/25/2001	CA2406403A1 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
10/25/2001	CA2406390A1 Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
10/25/2001	CA2406271A1 Substituted 1,4-thiazepine and analogs and their use as activators of caspases
10/25/2001	CA2406245A1 Il-174 uses, compositions and methods
10/25/2001	CA2406213A1 Compositions and methods for the therapy and diagnosis of breast cancer
10/25/2001	CA2406195A1 Lipid binding protein 4
10/25/2001	CA2406160A1 Compounds for modulating cell proliferation
10/25/2001	CA2406032A1 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase
10/25/2001	CA2406023A1 Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
10/25/2001	CA2405781A1 Secreted proteins
10/25/2001	CA2405709A1 Albumin fusion proteins
10/25/2001	CA2405701A1 Albumin fusion proteins
10/25/2001	CA2405696A1 5-substituted tetralones as inhibitors of ras farnesyl transferase
10/25/2001	CA2405684A1 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
10/25/2001	CA2405597A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	CA2405563A1 Albumin fusion proteins
10/25/2001	CA2405557A1 Albumin fusion proteins
10/25/2001	CA2405550A1 Albumin fusion proteins
10/25/2001	CA2405525A1 Albumin fusion proteins
10/25/2001	CA2405451A1 Molecules associated with human reproduction
10/25/2001	CA2404858A1 Treatment of neurodegenerative disease
10/25/2001	CA2404639A1 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
10/25/2001	CA2404097A1 Method and compositions for preventing hormone induced adverse effects
10/25/2001	CA2403644A1 Drug metabolizing enzymes
10/25/2001	CA2403508A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
10/25/2001	CA2403490A1 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001	CA2399940A1 Enhancement of antibody-mediated immune responses
10/25/2001	CA2398446A1 Pyrazoles for inhibiting protein kinases
10/24/2001	EP1148055A1 C9 taxane derivatives and pharmaceutical compositions containing them
10/24/2001	EP1147773A1 Medicinal compositions for treating osseous lesion in multiple myeloma
10/24/2001	EP1147413A2 Growth differentiation factor inhibitors and uses therefor
10/24/2001	EP1147223A1 Identifying, monitoring, and treating women for breast precancer or cancer
10/24/2001	EP1147214A1 A novel method for designing protein kinase inhibitors
10/24/2001	EP1147202A2 Plasminogen kringle 4 region fragments and methods of use
10/24/2001	EP1147190A1 Her-2/neu fusion proteins
10/24/2001	EP1147186A1 In vitro activated gamma delta lymphocytes
10/24/2001	EP1147179A2 Human liver progenitors
10/24/2001	EP1147124A2 Steroid sulfatase inhibitors and methods for making and using the same
10/24/2001	EP1147116A1 Boron steroid mimics and pharmaceutical compositions
10/24/2001	EP1147108A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
10/24/2001	EP1147107A1 Novel angiogenesis inhibitors
10/24/2001	EP1147102A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1147101A1 Reverse hydroxamate inhibitors of matrix metalloproteinases
10/24/2001	EP1147095A1 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
10/24/2001	EP1147093A1 Substituted bicyclic derivatives useful as anticancer agents
10/24/2001	EP1147092A1 Substituted imidazoles, their preparation and use
10/24/2001	EP1147091A2 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
10/24/2001	EP1147081A1 Carotenoid degradation products having an anti-tumoral effect
10/24/2001	EP1147079A2 Beta-phenylalanine derivatives as integrin antagonists
10/24/2001	EP1147078A1 Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1146912A1 Method for improved radiation therapy
10/24/2001	EP1146909A1 Method of treating cancer by restoration of pp32 function
10/24/2001	EP1146907A2 Use of cationic lipids to generate anti-tumor immunity
10/24/2001	EP1146903A1 Glypicans for the detection and treatment of human carcinoma
10/24/2001	EP1146901A1 Potentiation of anti-cd38-immunotoxin cytotoxicity
10/24/2001	EP1146897A1 Use of a melanoma inhibiting activity factor (mia) for cartilage and bone repair
10/24/2001	EP1146895A2 Methods for increasing circulating platelets for collection and cryopreservation using thrombopoietin compositions
10/24/2001	EP1146894A1 Uses of thank, a tnf homologue that activates apoptosis
10/24/2001	EP1146892A2 Baff, inhibitors thereof and their use in the modulation of the b-cell response
10/24/2001	EP1146889A2 Identification of specific differentially expressed mycobacterial antigens
10/24/2001	EP1146881A2 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
10/24/2001	EP1146875A1 Myt1 kinase inhibitors
10/24/2001	EP1146874A1 Vitronectin receptor antagonist
10/24/2001	EP1146873A1 Anti-androgens and methods for treating disease
10/24/2001	EP1146870A1 Antioxidant compositions and methods for companion animals
10/24/2001	EP1146869A2 Inhibition of stat3 signal transduction for human cancer therapy
10/24/2001	EP1146789A1 Treating cancers associated with overexpression of her-2/neu
10/24/2001	EP1146788A1 Amide derivatives for antiangiogenic and/or antitumorigenic use
10/24/2001	EP1146787A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
10/24/2001	EP1035824A4 A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
10/24/2001	EP0906295B1 Dibenzo-oxazepine and -dioxepine derivatives and their use as anti-tumor agents
10/24/2001	EP0869955B1 N-acyl-2-substituted-4-(benzimidazolyl- or imidazopyridinyl-substituted residues)-piperidines as tachykinin antagonists
10/24/2001	EP0858341B1 Combination therapy for advanced cancer comprising temozolomide and cisplatin
10/24/2001	EP0820433B1 O-malonyltyrosyl compounds, o-malonyltyrosyl compound-containing peptides, and uses thereof

1 ... 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 ... 2211